We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02365818
Recruitment Status : Completed
First Posted : February 19, 2015
Last Update Posted : April 14, 2021
Sponsor:
Information provided by (Responsible Party):
CG Oncology, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.

Condition or disease Intervention/treatment Phase
Bladder Cancer Biological: CG0070 Phase 2

Detailed Description:
The plan is to study the safety and efficacy of CG0070 in high-grade NMIBC (Non-muscle Invasive Bladder Cancer) patients who failed BCG therapy. Most patients with NMIBCis (Cis, Cis with Ta and/or T1, high grade Ta or T1 with frequent or uncontrolled recurrences) who have failed BCG (Bacillus Calmette-Guerin) intravesical therapy (standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a surgery associated with major morbidity, mortality and quality of life issues. Morbidity and long term tedious medical care will be for the rest of the patient's life span. Most patients at this stage do not show signs of disease progression into the muscle layer or of metastasis, making surgery a very difficult decision. CG0070, if successful in this trial, will serve to provide a therapeutic alternative for this patient population in need.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG (Bacillus Calmette-Guerin) Therapy and Refused Cystectomy
Actual Study Start Date : June 2, 2015
Actual Primary Completion Date : August 2018
Actual Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: CG0070
Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
 Biological: CG0070
Other Name: oncolytic adenovirus with a E2F promotor and expresses GMCSF


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Durable Complete Response Proportion (DCR) [ Time Frame: 18 months time point from the date of the first intravesical intervention ]
    Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention


Secondary Outcome Measures :
  1. Cystectomy Free Survival [ Time Frame: 18 months after the first intravesical treatment ]
    Not available, not collected on study or not currently available

  2. Complete Response Survival [ Time Frame: 18 months after the first intravesical treatment ]
    Not available, not collected on study or not currently available

  3. Progression Free Survival [ Time Frame: 18 months after the first intravesical treatment ]
    Not available, not collected on study or not currently available

  4. Time to Progression to Muscle Invasive Disease [ Time Frame: 18 months after the first intravesical treatment ]
    Not available, not collected on study or not currently available

  5. Overall Survival [ Time Frame: 18 months and 24 months after first intravesical treatment ]
    Not available, not collected on study or not currently available

  6. PD-L1 Status Changes [ Time Frame: changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months ]
    PD-L1 status of cancer cells and immune cells at tumor site by IHC

  7. Organ Confined Disease Proportions [ Time Frame: at cystectomy ]
    Patient proportions with no cancer cells in regional lymph nodes at cystectomy

  8. Complete Response Proportions [ Time Frame: 24 months after the first intravesical treatment ]
    Proportions of patients with a complete response of at least 12 months' duration

  9. PD-1 Status Changes [ Time Frame: changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months ]
    PD-1 status of immune cells at tumor site by IHC

  10. Disease Regression Proportions [ Time Frame: 24 months after the first intravesical treatment ]
    Proportions of patients with a partial response and/or a complete response of less than 12 months' duration


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have pathologically confirmed non-muscle invasive bladder cancer (NMIBC) high grade disease (HG), as defined by the 2004 WHO classification system
  2. Patients must have no evidence of muscle invasive disease
  3. Patients must be able to provide a sufficient biopsy sample to the central pathologist for histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial tumors with mixed histology (but with <50% variant) are eligible.
  4. Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. Bacillus Calmette-Guerin (BCG) must have been one of the prior therapies administered.
  5. Patients can have either failed BCG induction therapy within a six-month period or have been successfully treated with BCG, but subsequently found to have recurrence. The first standard course of intravesical BCG therapy must include at least six weekly treatments (allowable range of instillations per course is 4-9). The second course of BCG therapy must include at least two weekly treatments.

  6. Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the past. For those patients with only Ta or T1 disease at enrollment AND with no history of Cis, they must have

    • disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR
    • disease recurrence within 18 months of BCG maintenance OR
    • disease recurrence within 24 months of BCG induction
    • T1 patients need to have evidence of muscle included in their latest biopsy; and if not a re-TURBT has to be done prior to enrollment
  7. 18 years of age or older
  8. Radical cystectomy has been declined by the patient in a signed special section of the informed consent, whereby there is a clear explanation by the investigator to the subject that a delay of cystectomy may increase his/her chance of disease progression, the results of which may lead to serious and life threatening consequences.
  9. Patients must be able to enter into the study within ten weeks of their most recent diagnostic procedure, which is usually a diagnostic biopsy, a transurethral resection of bladder tumor (TURBT) procedure or positive urine cytology.
  10. Eastern Cooperative Oncology Group (ECOG) performance status <2.
  11. Not pregnant or lactating
  12. Patients with child bearing potential must agree to use adequate contraception
  13. Agree to study specific informed consent and HIPAA authorization for release of personal health information

  14. Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000 cells/mm^3

    • Adequate renal function: serum creatinine <2.5mg/dL
    • Bilirubin, AST and ALT not more than 2 x Upper Limits of Normal
    • PT/INR, PTT, and fibrinogen within institutional acceptable limits
    • Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070

Exclusion Criteria:

  1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable
  2. History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
  3. Known infection with HIV, HBV or HCV.
  4. Anticipated use of chemotherapy or radiotherapy not specified in the study protocol while on study
  5. Any underlying medical condition that, in the Investigator's opinion, will make the administration of study vector hazardous to the patient, would obscure the interpretation of adverse events, or not permit adequate surgical resection.
  6. Systemic treatment on any investigational clinical trial within 28 days prior to registration.
  7. Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ≤ 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.
  8. Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry.
  9. History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year
  10. History of stage III or greater cancer, excluding urothelial cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer, must have been adequately treated and have been disease-free for ≥ 2 years at the time of registration.

  11. Progressive or persistent viral or bacterial infection

    • All infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on study
    • Urinary tract infection, including particularly bladder infection, must be resolved prior to being placed on study
  12. Unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02365818


Locations
Show Show 17 study locations
Sponsors and Collaborators
CG Oncology, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Gary Steinberg, MD University of Chicago
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: CG Oncology, Inc.
ClinicalTrials.gov Identifier: NCT02365818    
Other Study ID Numbers: BOND 2 version 3.8
First Posted: February 19, 2015    Key Record Dates
Last Update Posted: April 14, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CG Oncology, Inc.:
Bladder Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Female Urogenital Diseases
 Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Urinary Bladder Diseases
Urologic Diseases
Male Urogenital Diseases